Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2 years in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trial
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ..
OBJECTIVES: The study aimed to evaluate the effect of adding a non-steroidal anti-inflammatory drug (NSAID), celecoxib (CEL), to a tumour necrosis factor inhibitor (TNFi), golimumab (GOL), compared with TNFi monotherapy on radiographic spinal progression in patients with radiographic axial spondyloarthritis (r-axSpA) over 2 years.
METHODS: R-axSpA patients, having risk factors for radiographic progression (high disease activity plus C reactive protein >5 mg/L and/or ≥1 syndesmophyte(s)), underwent a 12-week run-in phase with GOL 50 mg every 4 weeks. In the core phase (96 weeks), only patients with a good clinical response at week 12 were randomised (1:1) to GOL+CEL 200 mg two times per day (combination therapy) or GOL monotherapy. The primary endpoint was radiographic progression assessed by modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) change at week 108 in the intent-to-treat population.
RESULTS: A total of 128 patients were enrolled in the run-in phase; and 109 patients were randomised at week 12 to monotherapy (n=55) or combination therapy (n=54). At week 108, 97 (52 vs 45) patients completed the study. The change in mSASSS at week 108 was 1.7 (95% CI 0.8 to 2.6) in the monotherapy vs 1.1 (95% CI 0.4 to 1.8) in the combination therapy groups (p=0.79). New syndesmophytes occurred in 25% of patients in the monotherapy vs 11% of patients in the combination therapy groups (p=0.12). During the study, no significant differences in adverse events and serious adverse events were observed between the groups.
CONCLUSIONS: Combination therapy with GOL+CEL did not demonstrate statistically significant superiority over GOL monotherapy in retarding radiographic spinal progression over 2 years in r-axSpA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 83(2024), 5 vom: 11. Apr., Seite 599-607 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Proft, Fabian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Inflammatory Agents, Non-Steroidal |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 26.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/ard-2023-224699 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36718916X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36718916X | ||
| 003 | DE-627 | ||
| 005 | 20240426233550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240117s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/ard-2023-224699 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM36718916X | ||
| 035 | |a (NLM)38228361 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Proft, Fabian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2 years in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. | ||
| 520 | |a OBJECTIVES: The study aimed to evaluate the effect of adding a non-steroidal anti-inflammatory drug (NSAID), celecoxib (CEL), to a tumour necrosis factor inhibitor (TNFi), golimumab (GOL), compared with TNFi monotherapy on radiographic spinal progression in patients with radiographic axial spondyloarthritis (r-axSpA) over 2 years | ||
| 520 | |a METHODS: R-axSpA patients, having risk factors for radiographic progression (high disease activity plus C reactive protein >5 mg/L and/or ≥1 syndesmophyte(s)), underwent a 12-week run-in phase with GOL 50 mg every 4 weeks. In the core phase (96 weeks), only patients with a good clinical response at week 12 were randomised (1:1) to GOL+CEL 200 mg two times per day (combination therapy) or GOL monotherapy. The primary endpoint was radiographic progression assessed by modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) change at week 108 in the intent-to-treat population | ||
| 520 | |a RESULTS: A total of 128 patients were enrolled in the run-in phase; and 109 patients were randomised at week 12 to monotherapy (n=55) or combination therapy (n=54). At week 108, 97 (52 vs 45) patients completed the study. The change in mSASSS at week 108 was 1.7 (95% CI 0.8 to 2.6) in the monotherapy vs 1.1 (95% CI 0.4 to 1.8) in the combination therapy groups (p=0.79). New syndesmophytes occurred in 25% of patients in the monotherapy vs 11% of patients in the combination therapy groups (p=0.12). During the study, no significant differences in adverse events and serious adverse events were observed between the groups | ||
| 520 | |a CONCLUSIONS: Combination therapy with GOL+CEL did not demonstrate statistically significant superiority over GOL monotherapy in retarding radiographic spinal progression over 2 years in r-axSpA | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-Inflammatory Agents, Non-Steroidal | |
| 650 | 4 | |a Biological Therapy | |
| 650 | 4 | |a Spondylitis, Ankylosing | |
| 650 | 4 | |a Tumor Necrosis Factor Inhibitors | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 650 | 7 | |a Celecoxib |2 NLM | |
| 650 | 7 | |a JCX84Q7J1L |2 NLM | |
| 700 | 1 | |a Torgutalp, Murat |e verfasserin |4 aut | |
| 700 | 1 | |a Muche, Burkhard |e verfasserin |4 aut | |
| 700 | 1 | |a Rios Rodriguez, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Listing, Joachim |e verfasserin |4 aut | |
| 700 | 1 | |a Protopopov, Mikhail |e verfasserin |4 aut | |
| 700 | 1 | |a Rademacher, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Haibel, Hildrun |e verfasserin |4 aut | |
| 700 | 1 | |a Spiller, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Weber, Anne-Katrin |e verfasserin |4 aut | |
| 700 | 1 | |a Verba, Maryna |e verfasserin |4 aut | |
| 700 | 1 | |a Brandt-Juergens, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Kiltz, Uta |e verfasserin |4 aut | |
| 700 | 1 | |a Sieburg, Maren |e verfasserin |4 aut | |
| 700 | 1 | |a Jacki, Swen |e verfasserin |4 aut | |
| 700 | 1 | |a Sieper, Joachim |e verfasserin |4 aut | |
| 700 | 1 | |a Poddubnyy, Denis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 83(2024), 5 vom: 11. Apr., Seite 599-607 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2024 |g number:5 |g day:11 |g month:04 |g pages:599-607 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/ard-2023-224699 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2024 |e 5 |b 11 |c 04 |h 599-607 | ||